美国当地时间5月30日至6月3日，2025年美国临床肿瘤学会（ASCO）年会在美国芝加哥举行。该年会上，有70余项中国原 创研究成果入选，中国专家的发言数量再创新高。在此背景下，中国创新药备受资本市场关注。 国产创新药获认可 本报记者 何文英 方正证券创新药高级分析师李霁阳在接受《证券日报》记者采访时表示："中国创新药企的商业模式获得市场广泛认可， 究其原因，第一是相关龙头公司纷纷进入盈利阶段；第二是相关企业研发管线爆发，大额的BD（Business Development，即资 源整合）交易层出不穷，切实给企业带来丰厚的利润回报，因此创新药进入系统性拔高估值阶段，市场开始给予创新管线更多 估值溢价。" 上市公司积极布局 受益于国产创新药的认可度提升以及BD大单涌现，上市公司在创新药领域的布局也受到投资者的高度关注。 湖南华纳大药厂股份有限公司相关负责人对《证券日报》记者表示："公司自主研发的中药1.1类创新药乾清颗粒已完成Ⅱ 期临床试验，Ⅲ期临床试验相关筹备工作全面启动。公司持股的上海致根医药科技有限公司自主开发的具有全新结构的新型抗 抑郁药ZG-001胶囊，拟用于治疗成人伴有自杀意念或行为的重性抑郁障碍。 ...

而派恩加滨片是新一代KCNQ钾通道激动剂，为新型靶向抗癫痫药物。其Ⅰ期临床验证其安全耐受性优 异，Ⅱa期研究正在入组。作为难治性癫痫的创新疗法，该品种有望突破现有治疗局限，后续还将拓展 至儿童癫痫及抑郁共病领域，为广大患者提供新选择。 近年来，海南海药始终坚持人民至上、生命至上，加大战略性新兴产业布局，大力发展创新药，持续加 大研发投入，构建新型科研创新体系，推动企业从"仿创结合"向"创新驱动"发展转型，矢志打造海南自 贸港医药企业创新发展的标杆，力争让创新成为海南海药的金色名片。 据海南海药负责人王建平介绍，下一步，海南海药将充分利用海南自贸港生物医药政策优势，依托博鳌 乐城国际医疗旅游先行示范区药械创新平台，一方面把国外高端药械引进来，满足国内医疗市场潜在需 求，另一方面推动海南海药创新产品"走出去"，为构建人类卫生健康共同体贡献力量。 （文章来源：新华财经） 新华财经上海5月24日电（记者陈碧琪）新兴际华集团旗下驻琼上市公司海南海药（证券代码： SZ:000566）于24日在上海举办"创新驱动未来——海南海药创新药产品说明会"。记者从会上获悉，该 公司在一类化学新药氟非尼酮胶囊（适应症：器官纤维化疾病） ...

Group 1: Financial Performance and Strategy - The company aims to achieve profitability by enhancing R&D efforts and accelerating the launch of new products, with a focus on collaboration with universities and research institutions [1][2] - The company plans to optimize its international business management and deepen market penetration in Southeast Asia, Africa, and Latin America, enhancing its international operational capabilities [2][7] - The company is committed to reducing operational costs through strict budget management and cost-cutting measures [2][7] Group 2: Product Development and Clinical Trials - The company is advancing the clinical trials of its drugs, with the fluorofenone capsule expected to enter Phase III trials in the second half of 2025, having met its primary research endpoints in Phase II [4] - The company is conducting Phase IIa clinical research for the pain relief drug, with ongoing patient recruitment for different dosage cohorts [4][6] - The company is focusing on building a comprehensive product pipeline in the neuropsychiatric field and enhancing its traditional Chinese medicine offerings [3] Group 3: Market Challenges and Responses - The company has experienced a significant decline in sales revenue due to a slowing pharmaceutical market and economic conditions [6][7] - The company is actively participating in national procurement initiatives to maximize market potential and is focusing on key products and markets to drive growth [6][7] - The company acknowledges the challenges posed by strict regulatory requirements in drug approval processes, particularly for new epilepsy medications [5][6]